HOME >> BIOLOGY >> NEWS
Small-molecule inhibitors of anthrax lethal factor identified

Scientists have identified several compounds that block the activity of a key anthrax protein called lethal factor (LF)--an important first step in developing therapeutics to counter the disease.

Anthrax, a disease caused by the spore-forming bacterium Bacillus anthracis, is most deadly when exposure occurs through inhalation. Prompt diagnosis and antibiotic treatment during the early stages of infection are critical. In many cases, however, antibiotics may not be effective--particularly when bacterial overload causes large amounts of anthrax toxin to be released in the body.

Anthrax toxin consists of three proteins: lethal factor, protective antigen, and edema factor, all of which work in concert to kill host cells. While the exact mechanism of anthrax toxin is not yet well understood, it is clear that developing methods to inhibit toxin assembly and/or function is critically important.

In an article published in this month's issue of Nature Structural and Molecular Biology, investigators from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the National Cancer Institute (NCI), the Burnham Institute, and the Harvard Institutes of Medicine report using a high-throughput assay to screen a group of 1,990 compounds known as the NCI diversity set. The molecular properties of this group are predictive of a larger set of more than 100,000 compounds.

Using a two-stage screening assay, the team identified a number of compounds that inhibited the activity of LF. All inhibitors were further verified by high-performance liquid chromatography and their efficacy was validated in cell culture. Finally, molecular modeling techniques were used to predict structural features that contribute to inhibitor binding and potency.

These techniques revealed a common pharmacophore--a "scaffold" upon which future therapeutics can be built. This pharmacophore will serve as a basis for directing future effo
'"/>

Contact: Caree Vander Linden
Caree.Vander-Linden@amedd.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
22-Jan-2004


Page: 1 2

Related biology news :

1. Small-molecule inhibitors of botulinum neurotoxin identified
2. Chemical genetics identifies SARS inhibitors
3. COX-2 inhibitors and renal damage in obesity-related Type II diabetes
4. Researchers learn certain enzyme inhibitors may help in cancer therapy following initial procedures
5. Study offers new insights into angiogenesis inhibitors
6. COX-2 inhibitors may delay onset of breast cancer
7. Harvard Medical School researchers discover first in a new class of mitosis inhibitors
8. Researchers improve detection of diverse anthrax strains
9. Argonne scientists determine structure of staph, anthrax enzyme
10. Crystal structure for anthrax-cell binding complex
11. TIGR president discusses significance of finding anthrax toxin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology:
Cached News: